Insuman Comb 50 (Insulin Human (Rdna))

Insulin human mimics the action of natural human insulin. After subcutaneous injection it binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen storage, suppress hepatic glucose production, and regulate lipid metabolism, thereby lowering circulating glucose.

The dose of Insuman Comb 50 is individualized. A qualified healthcare professional determines the appropriate amount based on the patient’s blood glucose readings, carbohydrate intake, body weight, renal function and overall treatment goals. Patients should follow the prescriber’s instructions and adjust only under medical supervision.

Insulin is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta in harmful amounts. However, dosing may need adjustment. Breastfeeding mothers should consult their healthcare provider, as insulin is present in very low concentrations in breast milk and is usually safe when used as prescribed.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Insuman Comb 50 contains recombinant human insulin, which is structurally identical to endogenous insulin. Compared with rapid‑acting insulin analogues, it has a slightly longer onset and duration, making it suitable for basal or mixed regimens. It offers a cost‑effective alternative to brand‑name analogues while providing comparable glycemic control when used appropriately.

Insuman Comb 50 must be stored in a refrigerator at 2‑8 °C. Keep the vial or pen in its original packaging, protect it from direct light, and avoid freezing. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a limited period as indicated on the label, but should be discarded after the recommended in‑use time.

Insuman Comb 50 is administered by subcutaneous injection into the abdomen, thigh, or upper arm. The injection technique should follow standard aseptic practices, using a suitable needle or pen device. Patients should rotate injection sites to reduce the risk of lipodystrophy and follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from local skin reactions to anaphylaxis. Prompt recognition and treatment of low blood glucose, as well as immediate medical attention for any signs of a severe allergic response, are essential.

Insuman Comb 50 should not be used by individuals with a known hypersensitivity to human insulin or any of the product’s excipients. It is also contraindicated in patients experiencing hypoglycemia at the time of administration. Clinicians must evaluate each patient’s medical history before initiating therapy.